PCI in the patient with in stent restenosis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
Certain factors are known to increase the risk of in-stent [[restenosis]], which can be grouped into those that are related to the patient, the [[lesion]], and the procedure. Patients with [[diabetes mellitus]] and [[chronic kidney disease]] are at an increased risk of ISR. Lesions with a great lesion length, small vessel diameter, total [[plaque]] burden, chronic total [[occlusion]], ostial location, and/or vein graft lesion are more likely to experience in-stent [[restenosis]]. Additionally, procedure-related factors that increase the risk of ISR include a residual [[stenosis]] >30%, a residual [[pressure gradient]] >20mmHg, and an increased number, overlap, and length of [[stents]]. | Certain factors are known to increase the risk of in-stent [[restenosis]], which can be grouped into those that are related to the patient, the [[lesion]], and the procedure. Patients with [[diabetes mellitus]] and [[chronic kidney disease]] are at an increased risk of ISR. Lesions with a great lesion length, small vessel diameter, total [[plaque]] burden, chronic total [[occlusion]], ostial location, and/or vein graft lesion are more likely to experience in-stent [[restenosis]]. Additionally, procedure-related factors that increase the risk of ISR include a residual [[stenosis]] >30%, a residual [[pressure gradient]] >20mmHg, and an increased number, overlap, and length of [[stents]]. | ||
== | ==Treatment== | ||
The major goal of treating in-stent restenosis is to minimize the chance of recurrent [[restenosis]]. If a bare metal stent develops ISR, then a drug eluting stent should be placed. If ISR develops in a drug eluting stent, there is not data that a different type of drug eluting stent will prevent a recurrence (e.g. switching from sirolimus to paclitaxel). | |||
Revision as of 13:19, 13 May 2010
| Cardiology Network |
 Discuss PCI in the patient with in stent restenosis further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editors-In-Chief: Laura Nasrallah, M.D.; David M. Leder, M.D.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Background
In-stent restenosis (ISR) is the most frequent late complication of stent implantation. It occurs when there is a reoccurrence of stenosis around a lesion that has been treated with a stent, and it results from exaggerated neointimal formation and is principally composed of smooth muscle cells and extracellular matrix. Although ISR has traditionally occurred in 10-80% of treated lesions, its incidence has been dramatically reduced by the development of drug-eluting stents.
Certain factors are known to increase the risk of in-stent restenosis, which can be grouped into those that are related to the patient, the lesion, and the procedure. Patients with diabetes mellitus and chronic kidney disease are at an increased risk of ISR. Lesions with a great lesion length, small vessel diameter, total plaque burden, chronic total occlusion, ostial location, and/or vein graft lesion are more likely to experience in-stent restenosis. Additionally, procedure-related factors that increase the risk of ISR include a residual stenosis >30%, a residual pressure gradient >20mmHg, and an increased number, overlap, and length of stents.
Treatment
The major goal of treating in-stent restenosis is to minimize the chance of recurrent restenosis. If a bare metal stent develops ISR, then a drug eluting stent should be placed. If ISR develops in a drug eluting stent, there is not data that a different type of drug eluting stent will prevent a recurrence (e.g. switching from sirolimus to paclitaxel).